Progress in understanding and treating idiopathic pulmonary fibrosis: Recent insights and emerging therapies
H Guo, J Sun, S Zhang, Y Nie, S Zhou… - Frontiers in …, 2023 - frontiersin.org
Idiopathic pulmonary fibrosis (IPF) is a long-lasting, continuously advancing, and irrevocable
interstitial lung disorder with an obscure origin and inadequately comprehended …
interstitial lung disorder with an obscure origin and inadequately comprehended …
Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials
S MacIsaac, D Somboonviboon… - Expert Opinion on …, 2024 - Taylor & Francis
Introduction Idiopathic pulmonary fibrosis (IPF) is a progressive, debilitating lung disease
with poor prognosis. Although two antifibrotics have been approved in the past decade there …
with poor prognosis. Although two antifibrotics have been approved in the past decade there …
A phosphodiesterase-4 inhibitor reduces lung inflammation and fibrosis in a hamster model of SARS-CoV-2 infection
Introduction The Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)
infection involves pulmonary inflammation that can progress to acute respiratory distress …
infection involves pulmonary inflammation that can progress to acute respiratory distress …
PDE4B inhibition by nerandomilast: Effects on lung fibrosis and transcriptome in fibrotic rats and on biomarkers in human lung epithelial cells
D Reininger, K Fundel‐Clemens… - British Journal of …, 2024 - Wiley Online Library
Background and Purpose The PDE4 family is considered a prime target for therapeutic
intervention in several fibro‐inflammatory diseases. We have investigated the molecular …
intervention in several fibro‐inflammatory diseases. We have investigated the molecular …
Discovery of amentoflavone as a natural PDE4 inhibitor with anti-fibrotic effects
Z Chen, Y Shi, F Zhong, K Zhang, F Zhang, S Xie… - Chinese Chemical …, 2024 - Elsevier
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with high mortality rate but
effective therapeutics are still lacking. Phosphodiesterase-4 (PDE4) inhibitors were reported …
effective therapeutics are still lacking. Phosphodiesterase-4 (PDE4) inhibitors were reported …
[HTML][HTML] Endothelial phosphodiesterase 4B inactivation ameliorates endothelial-to-mesenchymal transition and pulmonary hypertension
Y Xing, Y Hou, T Fan, R Gao, X Feng, B Li… - … Pharmaceutica Sinica B, 2024 - Elsevier
Pulmonary hypertension (PH) is a fatal disorder characterized by pulmonary vascular
remodeling and obstruction. The phosphodiesterase 4 (PDE4) family hydrolyzes cyclic AMP …
remodeling and obstruction. The phosphodiesterase 4 (PDE4) family hydrolyzes cyclic AMP …
[引用][C] Fibrotic lung disease: early signs, treatment and outcomes
I Belo - 2024 - Inst för medicin, Solna/Dept of …